Latest News and Press Releases

Longeveron announces planned transitions on its Board of Directors.

Longeveron to report Q1 2024 financial results on May 14, 2024.

Longeveron to present at investor conference - Planet MicroCap Showcase - May 1, 2024.

Longeveron raises $11.4 million in gross proceeds from warrent exercise offering and public offering.

Longeveron raises gross proceeds of ~$6.2 M from exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its common stock.

Data from Longeveron's CLEAR MIND Phase 2a clinical trial evaluating Lomecel-B in Alzheimer’s Disease has been accepted for two presentations at AAIC.

Longeveron announces closing of previously announced public offering, raising $5.25 million in gross proceeds.

Longeveron prices $5.15 million public offering with certain board member and insider participation.

CEO Letter to Shareholders. Update on overall strategy, business objectives, approach to capital allocation, and 2024 key priorities and goals.

MIAMI, March 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical...